| Followers | 0 |
| Posts | 36 |
| Boards Moderated | 0 |
| Alias Born | 03/02/2006 |
Monday, June 26, 2006 3:11:20 PM
Do DD
(or can I call you E?
)
It's hard to really be sure what Tercica is saying when reading the press release. When they say that
"In 22 patients with severe Primary IGFD, up to four times daily blood glucose measurements were made before and for up to seven days after initiation of Increlex treatment. The results showed no statistically significant difference in the frequency of hypoglycemia observed before versus after the start of Increlex (7.0% and 8.8%, respectively; p=0.48)."
we have no idea how many days they studied the patients prior to starting Increlex and thus no idea how many blood samples they took (population size from which to derive probability of hypoglycemia). We have a rough idea of how long they continued doing so after treatment began (up to 7 days). So after treatment, they most likely had at least a few hundred samples.
If you have a link to a site where there is more info about this study, I'd be happy to see it.
Most importantly, they don't say anything about how the blood samples were analyzed (statistically, that is). Consequently, it's hard to say just how sensitive the test was... did they do any form of multiple regression that could take into account the individual patient idiosyncracies, possible diurnal variation etc. Or did they lump all of the data from each patient into one bin to get a frequency of hypoglycemic episodes?
The P value usually refers to whether the null hypothesis (generally that there is no significant difference between treatment groups) can be rejected. A p value of 0.48 pretty much shouts out "Not significant". As for correlation, I'm used to r values being used as the variable, but even an r value of 0.48 would be pretty poor correlation, if I recall my stats courses correctly. Mind you, it's been many years.
Best wishes,
GS
(or can I call you E?
It's hard to really be sure what Tercica is saying when reading the press release. When they say that
"In 22 patients with severe Primary IGFD, up to four times daily blood glucose measurements were made before and for up to seven days after initiation of Increlex treatment. The results showed no statistically significant difference in the frequency of hypoglycemia observed before versus after the start of Increlex (7.0% and 8.8%, respectively; p=0.48)."
we have no idea how many days they studied the patients prior to starting Increlex and thus no idea how many blood samples they took (population size from which to derive probability of hypoglycemia). We have a rough idea of how long they continued doing so after treatment began (up to 7 days). So after treatment, they most likely had at least a few hundred samples.
If you have a link to a site where there is more info about this study, I'd be happy to see it.
Most importantly, they don't say anything about how the blood samples were analyzed (statistically, that is). Consequently, it's hard to say just how sensitive the test was... did they do any form of multiple regression that could take into account the individual patient idiosyncracies, possible diurnal variation etc. Or did they lump all of the data from each patient into one bin to get a frequency of hypoglycemic episodes?
The P value usually refers to whether the null hypothesis (generally that there is no significant difference between treatment groups) can be rejected. A p value of 0.48 pretty much shouts out "Not significant". As for correlation, I'm used to r values being used as the variable, but even an r value of 0.48 would be pretty poor correlation, if I recall my stats courses correctly. Mind you, it's been many years.
Best wishes,
GS
Recent INSM News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/17/2026 08:43:36 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/16/2026 08:17:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2026 08:41:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 08:01:21 PM
- Insmed Provides Clinical Update on Phase 2b CEDAR Study • PR Newswire (US) • 04/07/2026 08:01:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/06/2026 08:42:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:07:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/01/2026 09:10:46 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/01/2026 08:03:54 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/01/2026 08:02:49 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/01/2026 08:01:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/31/2026 08:13:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/30/2026 09:31:03 PM
- Insmed shares rise after UTHR trial data and Morgan Stanley upgrade • IH Market News • 03/30/2026 03:04:13 PM
- Insmed shares rise on positive results from ARIKAYCE Phase 3b study • IH Market News • 03/23/2026 02:34:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/23/2026 11:00:30 AM
- Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease • PR Newswire (US) • 03/23/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 08:05:20 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/19/2026 08:57:15 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2026 09:59:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 09:16:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 09:15:10 PM
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 03/05/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 09:14:51 PM
